Data Cubed’s new CCO David Kiger – who has held roles at Bioclinica and Parexel – says the company is primed to be the go-to provider as the industry continues to shift to virtual clinical trials.
Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.
Marking its sixth acquisition since 2017, BioIVT this week purchased Biological Specialty Corporation (BSC), which expands its ability to offer fresh blood products.
RxCelerate is opening its first office in the US to be closer to clients and meet a "huge demand" for drug discovery and development services in the greater Boston area.
Vertex was granted marketing authorization for its cystic fibrosis therapy in a combination regimen, marking the company’s third treatment for the condition to reach the market.
Advanced Clinical is partnering with Cognitive Clinical Trials to overcome recruitment road blocks in Alzheimer’s clinical trials and expedite research through patient centric model.
The decision, influenced by the expected loss of exclusivity for Restasis, will allow the company to ‘improve efficiencies’ across its manufacturing network, a spokesperson explained.
The Association of Clinical Research Professionals (ACRP) is developing competence standards for principal investigators (PIs) as part of its goal to reduce variability in performance across various clinical research roles.
CROs this month have made significant new hires with WCG adding eight to its scientific leadership team, PPD hiring four, and BioIVT filling its new-created role of CCO.
Also, making the move from Bioclinica, David Kiger has been named...
A study published by graduate students at MIT showed that a synthetic mRNA-based ‘programming language’ can control protein expression in gene therapy.
LabCorp has launched Pixel by LabCorp, a consumer-initiated wellness test offering that allows for sample self-collection and access to online results.
After Pharm-Olam conducted an orphan disease trial for therapy for a rare blood disorder, the European Commission granted it marketing authorization, and FDA is to give it priority review.
The lawsuit cites more than 150 alleged clinical trial-related deaths since 2014 with plaintiffs calling on the FDA to update current informed consent regulations.
